What is Zacks Research’s Estimate for APVO Q2 Earnings?

Aptevo Therapeutics Inc. (NASDAQ:APVO) – Equities researchers at Zacks Research issued their Q2 2026 earnings estimates for Aptevo Therapeutics in a research note issued to investors on Tuesday, June 16th. Zacks Research analyst D. Bautz anticipates that the biotechnology company will earn ($5.83) per share for the quarter. The consensus estimate for Aptevo Therapeutics’ current full-year earnings is ($24.13) per share. Zacks Research also issued estimates for Aptevo Therapeutics’ Q3 2026 earnings at ($5.38) EPS, Q4 2026 earnings at ($5.14) EPS, FY2026 earnings at ($22.57) EPS, FY2027 earnings at ($2.78) EPS and FY2028 earnings at ($2.36) EPS.

A number of other research firms also recently issued reports on APVO. Wall Street Zen upgraded shares of Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 29th. Weiss Ratings upgraded shares of Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Aptevo Therapeutics presently has an average rating of “Hold”.

Aptevo Therapeutics Stock Down 2.7%

Aptevo Therapeutics stock opened at $4.67 on Friday. The stock has a market cap of $5.84 million, a price-to-earnings ratio of -0.02 and a beta of 1.68. Aptevo Therapeutics has a 12-month low of $3.80 and a 12-month high of $91.44. The business’s 50-day simple moving average is $4.88 and its 200 day simple moving average is $8.06.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($6.41) earnings per share for the quarter, hitting the consensus estimate of ($6.41).

Hedge Funds Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC acquired a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned approximately 1.16% of Aptevo Therapeutics as of its most recent SEC filing. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.